EuroBiotech: More Articles of Note


> Boehringer Ingelheim and Zealand Pharma moved dual-acting GLP-1/glucagon agonist BI 456906 into a phase 2 trial in diabetes and obesity. The start of the trial will trigger a €20 million ($22 million) milestone payment to Zealand. Release 

> UniQure’s pivotal hemophilia B gene therapy trial hit its enrollment target. UniQure plans to continue adding up to six patients throughout September, taking it above the target. Statement 

> Valo Therapeutics acquired oncolytic virus technology from the University of Helsinki. Release 


Digitize remote site monitoring with Box

Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing.

> Macrophage Pharma named Søren Bregenholt as its CEO. Bregenholt previously held senior roles at Symphogen and IO Biotech. Statement 

> Gyroscope Therapeutics raised £50.4 million ($60.6 million) to fund clinical development of a dry age-related macular degeneration gene therapy. Syncona provided most of the money. Release (PDF)

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.